Leiner to redistribute products
This article was originally published in The Tan Sheet
Executive Summary
FDA's Atlanta District Office grants Leiner Healthcare Products permission to begin distributing previously manufactured OTC products if a third-party quality assessment deems the products acceptable under FDA methodology. In an Oct. 22 Securities and Exchange Commission filing, the Carson, Calif.-based firm says it will begin re-distributing a portion of its inventory in December. Leiner suspended its U.S. OTC production and distribution March 20 and initiated a voluntary recall in April after FDA found GMP discrepancies at the firm's Fort Mill, S.C., facility (1"The Tan Sheet" Sept. 24. 2007, p. 12)
You may also be interested in...
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.